Original articleReduction of contact factors in sickle cell disease†
References (37)
Diagnosis and management of disseminated intravascular coagulation: The role of heparin therapy
Blood
(1982)- et al.
Disseminated intravascular coagulation (DIC): An approach
Am J Med
(1972) - et al.
Fitzgerald factor (high molecular weight kininogen) clotting activity in human plasma in health and disease in various animal plasmas
Blood
(1976) - et al.
Platelet function in sickle cell anemia
Thrombos Res
(1977) - et al.
Evidence for a new plasma thromboplastin factor. I. Case report, coagulation studies and physicochemical properties
Blood
(1965) - et al.
Immunoelectrophoretic studies of prekallikrein in human plasma
Thrombos Res
(1982) Disseminated intravascular coagulation: A clinical/laboratory study of 48 patients
Ann NY Acad Sci
(1981)- et al.
The syndrome of disseminated intravascular coagulation
Rev Surg
(1963) Pathophysiology of generalized intravascular coagulation
Semin Thrombos Haemost
(1971)The clinical challenge of disseminated intravascular coagulation
N Engl J Med
(1970)
Consumption of serum factors and prothrombin during intravascular clotting in rabbits
Scand J Haematol
Radioimmunoassay of human Hageman factor (factor XII)
J Lab Clin Med
Human plasma prekallikrein (Fletcher factor) clotting activity and antigen in health and disease
J Lab Clin Med
Rheological aspects of sickle cell disease
Arch Intern Med
Hemostatic alterations accompanying sickle cell pain crisis
J Lab Clin Med
A plasma inhibitor of ristocetin-induced platelet aggregation in patients with sickle hemoglobinopathies
Am J Hematol
Platelet function and survival in sickle cell disease
J Lab Clin Med
Factor VIII (antihaemophilic factor) activity in sickle-cell anemia
Br J Haematol
Cited by (21)
High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease
2020, Journal of Thrombosis and HaemostasisThe role of platelets in sickle cell disease
2019, PlateletsHow I diagnose and treat venous thromboembolism in sickle cell disease
2018, BloodCitation Excerpt :Decreases in anticoagulant proteins, such as proteins C and S, have been reported in SCD and likely contribute to the hypercoagulable state.8,14 Finally, the possible role for iron in hypercoagulability has been suggested by decreased ex vivo measures of clotting, as measured by thromboelastography, in the plasma of SCD patients after iron chelation.34 Platelet activation may further promote clot formation.
Thrombin generation and cell-dependent hypercoagulability in sickle cell disease
2016, Journal of Thrombosis and HaemostasisCoagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies
2016, Blood ReviewsCitation Excerpt :While this may reflect the contribution of endothelial and sub-endothelial TF at sites of vascular injury that is not measured in blood, it may also reflect a contribution of activation of the intrinsic pathway to in vivo thrombin generation. Indeed, plasma levels of contact system proteins, including factor XII, prekallikrein and high molecular weight kininogen have been shown to be decreased in patients with SCD at “steady state” compared with control subjects, with further decreases during acute painful episodes [50–52]. Autoactivation of contact system proenzymes is known to occur on negatively charged surfaces.
- †
Supported in part by Grants HL0166 and HL28348 from the National Heart, Lung, and Blood Institute, the National Institutes of Health, and by a grant-in-aid from the American Heart Association and its Northeast Ohio Affiliate. Dr. Gordon is the recipient of a New Investigator Research Award from the National Institutes of Health.